OAM
KRYS icon

Oberweis Asset Management’s Krystal Biotech KRYS Stock Holding History

Oberweis Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,800
Closed -$8.44M – 199
2025
Q1 		$8.44M Hold
46,800
– – 0.42% 85
2024
Q4 		$7.33M Hold
46,800
– – 0.35% 110
2024
Q3 		$8.52M Buy
46,800
+4,200
+10% +$810K 0.44% 88
2024
Q2 		$7.82M Buy
42,600
+6,900
+19% +$1.16M 0.48% 78
2024
Q1 		$6.35M Buy
+35,700
New +$4.96M 0.46% 87

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Oberweis Asset Management's KRYS Position: Q2 2025 in Review

Oberweis Asset Management sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 46,800 shares — an estimated $8.44M sold.

Oberweis Asset Management first reported a position in KRYS in Q1 2024 and held it in 5 quarters. The position peaked at $8.52M in Q3 2024. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Oberweis Asset Management reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Oberweis Asset Management sold 46,800 Krystal Biotech shares in Q2 2025, an estimated $8.44M.
  • Oberweis Asset Management first reported a position in Krystal Biotech in Q1 2024 and held it in 5 quarters.
  • Oberweis Asset Management's Krystal Biotech position peaked at $8.52M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Oberweis Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.